South America
field trial
glucose metabolism disorders
population
primary prevention
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
18 04 2019
18 04 2019
Historique:
received:
22
02
2019
revised:
12
04
2019
accepted:
15
04
2019
entrez:
21
4
2019
pubmed:
21
4
2019
medline:
29
10
2019
Statut:
epublish
Résumé
The objective of the demonstration project for type 2 diabetes prevention in the Barranquilla and Juan Mina (DEMOJUAN) study was to investigate the extent to which it is possible to reach normal glucose metabolism with early lifestyle interventions in people at high risk of type 2 diabetes (prediabetes), compared with those who receive standard usual care. DEMOJUAN was a randomized controlled trial conducted in Juan Mina and Barranquilla, Northern Colombia. Eligible participants were randomized into one of three groups (control group, initial nutritional intervention, and initial physical activity intervention). The duration of the intervention was 24 months. The main study outcome in the present analysis was reversion to normoglycemia. Relative risks and their corresponding 95% confidence intervals were calculated for reversal to normoglycemia and T2D incidence. There was no statistically significant association between the intervention groups and reversion to normoglycemia. The relative risk of reversion to normoglycemia was 0.88 (95% CI 0.70-1.12) for the initial nutritional intervention group participants and 0.95 (95% CI 0.75-1.20) for the initial physical activity intervention group participants. Our study did not find any statistically significant differences in reversion to normoglycemia or the development of type 2 diabetes between the intervention groups and the control group in this population.
Sections du résumé
BACKGROUND
The objective of the demonstration project for type 2 diabetes prevention in the Barranquilla and Juan Mina (DEMOJUAN) study was to investigate the extent to which it is possible to reach normal glucose metabolism with early lifestyle interventions in people at high risk of type 2 diabetes (prediabetes), compared with those who receive standard usual care.
METHODS
DEMOJUAN was a randomized controlled trial conducted in Juan Mina and Barranquilla, Northern Colombia. Eligible participants were randomized into one of three groups (control group, initial nutritional intervention, and initial physical activity intervention). The duration of the intervention was 24 months. The main study outcome in the present analysis was reversion to normoglycemia. Relative risks and their corresponding 95% confidence intervals were calculated for reversal to normoglycemia and T2D incidence.
RESULTS
There was no statistically significant association between the intervention groups and reversion to normoglycemia. The relative risk of reversion to normoglycemia was 0.88 (95% CI 0.70-1.12) for the initial nutritional intervention group participants and 0.95 (95% CI 0.75-1.20) for the initial physical activity intervention group participants.
CONCLUSIONS
Our study did not find any statistically significant differences in reversion to normoglycemia or the development of type 2 diabetes between the intervention groups and the control group in this population.
Identifiants
pubmed: 31003515
pii: ijerph16081403
doi: 10.3390/ijerph16081403
pmc: PMC6518277
pii:
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Medicine (Baltimore). 2018 Jan;97(1):e9285
pubmed: 29505512
Lancet Diabetes Endocrinol. 2014 Jan;2(1):19-29
pubmed: 24622666
BMJ. 2017 Jun 30;357:j2835
pubmed: 28667088
Diabetologia. 2003 Mar;46(3):322-9
pubmed: 12687329
Eur Heart J. 2007 Jan;28(1):88-136
pubmed: 17220161
Int J Epidemiol. 2005 Feb;34(1):215-20
pubmed: 15333621
Perm J. 2016 Fall;20(4):15-241
pubmed: 27828773
Diabetes Care. 1997 Apr;20(4):537-44
pubmed: 9096977
Exp Clin Endocrinol Diabetes. 2008 Mar;116(3):167-72
pubmed: 18350480
Diabet Med. 2008 May;25(5):597-605
pubmed: 18445174
Epidemiology. 1990 Jan;1(1):65-71
pubmed: 2081242
Diabetes Care. 2010 Oct;33(10):2146-51
pubmed: 20664020
Diabetologia. 2012 May;55(5):1319-28
pubmed: 22322921
JAMA. 1999 Jun 2;281(21):2005-12
pubmed: 10359389
BMC Public Health. 2011 Nov 25;11:893
pubmed: 22117618
Int J Environ Res Public Health. 2014 Mar 04;11(3):2683-97
pubmed: 24599042
Diabetologia. 2006 Feb;49(2):289-97
pubmed: 16391903
Hypertension. 2004 Jan;43(1):25-30
pubmed: 14656958
Lancet. 2006 Sep 23;368(9541):1096-105
pubmed: 16997664
Public Health Nutr. 2006 Apr;9(2):258-65
pubmed: 16571181
Diabetes Metab Res Rev. 2013 Sep 2;:
pubmed: 23996584
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
BMC Public Health. 2007 Sep 19;7:249
pubmed: 17877832
BMC Public Health. 2017 Feb 15;17(1):198
pubmed: 28202029
Diabetes Care. 2004 Jan;27(1):155-61
pubmed: 14693982
Prim Care Diabetes. 2017 Feb;11(1):86-93
pubmed: 27727004
Diabetes. 2005 Apr;54(4):1150-6
pubmed: 15793255
Am J Prev Med. 2008 Oct;35(4):357-63
pubmed: 18779029
Am J Epidemiol. 1988 Jan;127(1):87-94
pubmed: 3337078
Health Aff (Millwood). 2012 Jan;31(1):67-75
pubmed: 22232096
Diab Vasc Dis Res. 2005 May;2(2):67-72
pubmed: 16305061
N Engl J Med. 2001 May 3;344(18):1343-50
pubmed: 11333990
Diabetes Care. 2004 Feb;27(2):407-14
pubmed: 14747221
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
pubmed: 20042775
Diabetes Care. 2003 Mar;26(3):725-31
pubmed: 12610029
Diabetes Care. 2005 May;28(5):1187-94
pubmed: 15855587
BMC Public Health. 2009 Sep 16;9:342
pubmed: 19758428
Diabetes Res Clin Pract. 2005 Feb;67(2):152-62
pubmed: 15649575
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
Chronic Illn. 2011 Dec;7(4):279-90
pubmed: 21840914
Diabetes Metab. 2011 Apr;37(2):144-51
pubmed: 21144787